Treatment of negative symptoms in schizophrenia

Psychopharm Review

Volumn 46, Issue 5, 2011, Pages 33-39

  Rado, Jeffrey T ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARMODAFINIL; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RITANSERIN; SILDENAFIL; TRAZODONE;

ADD ON THERAPY; ALOGIA; ALPHA RHYTHM; ANHEDONIA; ANTERIOR CINGULATE; ANTISOCIAL BEHAVIOR; AVOLITION; BLUNTED AFFECT; BRAIN BLOOD FLOW; COGNITIVE DEFECT; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; GRAY MATTER; HUMAN; HUMAN RELATION; INSULA; MENTAL PATIENT; META ANALYSIS (TOPIC); MIDDLE FRONTAL GYRUS; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SPEECH DISORDER; TEMPORAL GYRUS; TEMPORAL LOBE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION;

EID: 80052869567     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.IDT.0000396484.87192.42     Document Type: Review

References (50)

1. Kirkpatrick B, Fenton WS, Carpenter WT, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.
2. Makinen J, Miettunen J, Jaaskelainen E, et al. Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Res. 2010;178:121-125.
3. Andraeson NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 1989;7:49-58.
4. Kay SR, Fishbein A, Opter LA. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-266.
5. Husted JA, Beiser M, Iacono WG. Negative symptoms and the early course of schizophrenia. Psychiatry Res. 1992;43(3):215-222.
6. Malla AK, Norman RMG, Takhar J, et al. Can patients at risk for persistent negative symptoms be identified during their first episode or psychosis. J Nerv Ment Dis. 2004;192(7):455-463. (Pubitemid 38918061)
7. Eaton WW, Thara R, Federman B, et al. Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry. 1995;52(2):127-134.
8. Herbener ES, Harrow M. Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients. Schizophr Bull. 2001;27(3):527-537. (Pubitemid 33081703)
9. Bottlender R, Wegner U, Wittman J, et al. Deficit syndromes in schizophrenia patient 15 years after their first hospitalization: preliminary results of a follow-up study. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 4):27-36.
10. Cohen AL, Brown LA, Minor KS. The psychiatric symptomatology of deficit schizophrenia: a metaanalysis. Schizophr Res. 2010;118(1-3):122-127.
11. Trotman HD, Kirkpatrick B, Compton MT. Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features [published online ahead of print September 2, 2010]. Schizophr Res. Accessed January 5, 2011.
12. Tsai J, Lysaker PH, Vohs JL. Negative symptoms and concomitant attention deficits in schizophrenia: associations with prospective assessments of anxiety, social dysfunction, and avoidant coping. J Ment Health. 2010;19(2):184-192.
13. Bowie CR, Reichenberg A, Patterson TL, et al. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163:418-425. (Pubitemid 44469383)
14. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506. (Pubitemid 40343916)
15. Anderson JE, Wible CG, McCarley RW, et al. An MRI study of temporal lobe abnormalities and negative symptoms in chronic schizophrenia. Schizophr Res. 2002;58:123-134. (Pubitemid 35284504)
16. Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. 2001;158(2):234-243. (Pubitemid 32116521)
17. Hill K, Mann L, Laws KR, et al. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004;110:243-256. (Pubitemid 39278982)
18. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-447.
19. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
20. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564. (Pubitemid 36682312)
21. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610. (Pubitemid 44464569)
22. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of secondgeneration antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
23. Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;(3):CD005581.
24. Singh SP, Singh V, Kar Nilamadhab, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197:174-179.
25. Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 2010;179:19-23.
26. Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Neuro-Psychopharmacol Biol Psychiatry. 2011;15;35(1):208-211.
27. Hanson E, Healey K, Wolf D, et al. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep. 2010;12:563-571.
28. Pierre JM, Peloian JH, Wirshing DA, et al. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry. 2007;68(5):705-710. (Pubitemid 46841853)
29. Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry. 2005;66(7):839-843. (Pubitemid 41032824)
30. Freudenrich O, Henderson DC, Macklin EA, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind placebo-controlled pilot trial. J Clin Psychiatry. 2009;70:1674-1680.
31. Kane JM, D'Souza DC, Patkar AA, et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebocontrolled study. J Clin Psychiatry. 2010;71(11):1475-1481.
32. Akhondzadeh S, Ghayyoumi R, Rezaci F, et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology. 2011;213(4):809-815.
33. Tang W-K, Ungvari GS. Efficacy of electroconvulsive therapy combined with antipsychotic medications in treatment-resistant schizophrenia: a prospective, open trial. J ECT. 2002;18(2):90-94. (Pubitemid 35006026)
34. Chanpattana W, Sackeim HA. Electroconvulsive therapy in treatment-resistant schizophrenia: prediction of response and the nature of symptomatic improvement. J ECT. 2010;26(4):289-298.
35. Matheson SL, Green MJ, Loo C, et al. Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta-review. Schizophr Res. 2010;118:201-210.
36. Janicak PG, Dowd SM, Rado JT, et al. The (re)emerging role of therapeutic neuromodulation. Curr Psychiatry. 2010;9(11):66-74.
37. Cohen E, Bernardo M, Mansana J, et al. Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. J Neurol Neurosurg Psychiatry. 1999;67(1):129-130. (Pubitemid 29278354)
38. Jandl M, Bittner R, Sack A, et al. Changes in negative symptoms and EEG in schizophrenic patients after repetitive transcranial magnetic stimulation (rTMS): an open-label pilot study. J Neural Transm. 2005;112:955-967. (Pubitemid 40869084)
39. Jin Y, Potkin SG, Kemp AS, et al. Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (αTMS) on the negative symptoms of schizophrenia. Schizophr Bull. 2006;32(3):556-561. (Pubitemid 43992328)
40. Holi MM, Eronen M, Toivonev K, et al. Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophr Bull. 2004;30(2):429-434. (Pubitemid 38828546)
41. Hajak G, Marienhagen J, Langguth B, et al. Highfrequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychol Med. 2004;34:1157-1163. (Pubitemid 39517146)
42. Novak T, Horacek J, Mohr P, et al. The double-blind sham-controlled study of high-frequency rTMS (20 Hz) for negative symptoms in schizophrenia: negative results. Neuroendocrinol Lett. 2006;27(1/2):209-213. (Pubitemid 43970795)
43. Mogg A, Purvis R, Eranti S, et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr Res. 2007;93:221-228. (Pubitemid 46817960)
44. Prikryl R, Kasparek T, Skotakova S, et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr Res. 2007;95:151-157. (Pubitemid 47313654)
45. Goyal N, Nizamie SH, Desarkar P. Efficacy of adjuvant high frequency repetitive transcranial magnetic stimulation on negative and positive symptoms of schizophrenia: preliminary results of a double-blind sham-controlled study. J Neuropsychiatry Clin Neurosci. 2007;19:464-467. (Pubitemid 350156107)
46. Schneider AL, Schneider TL, Stark H. Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study. Brain Stimul. 2008;1:106-111. (Pubitemid 351689965)
47. Klein E, Kolsky Y, Puyerovsky M, et al. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biol Psychiatry. 1999;46:1451-1454.
48. Fitzgerald PB, Herring S, Hoy K, et al. A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimul. 2008;1:27-32. (Pubitemid 351966358)
49. Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res. 2009;108:11-24.
50. Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry. 2010;71(4):411-418.